Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics (NASDAQ: ABCL) operates at the intersection of biotechnology and drug discovery, making its news feed particularly relevant for investors tracking the antibody therapeutics space. As a platform company that partners with pharmaceutical giants to discover monoclonal antibodies, AbCellera's announcements often signal broader trends in the therapeutics pipeline landscape.
News coverage for ABCL typically centers on partnership announcements and program milestones. When AbCellera discloses new collaborations or reports that partner programs have advanced to new clinical phases, these developments directly impact the company's future milestone and royalty revenue streams. Each clinical trial progression represents both validation of the discovery platform and potential future income.
Quarterly earnings releases reveal how AbCellera's partnership economics translate into financial performance. Beyond headline numbers, these reports detail the status of partner programs, new agreements signed, and updates on the company's proprietary internal pipeline. For a platform-based biotech, understanding the partnership pipeline is essential context.
Clinical trial updates feature prominently in AbCellera's news flow. The company's internal programs generate announcements around trial initiations, interim data readouts, and regulatory interactions. Additionally, positive developments from partner programs—where AbCellera discovered the underlying antibody—often merit disclosure given milestone payment implications.
Patent and intellectual property news matters for platform companies. AbCellera's microfluidic technology represents a core competitive advantage, and developments related to patent protection or technology licensing can affect the company's market position.
Bookmark this page to follow AbCellera's developments as the company advances its antibody discovery platform and expands its therapeutic pipeline.
AbCellera (Nasdaq: ABCL) will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). A live audio webcast of the presentation will be available on AbCellera's Investor Relations website, along with a replay after the event.
AbCellera specializes in finding antibodies through the analysis of natural immune systems, partnering with various drug developers to accelerate drug development while minimizing costs. For further details, visit www.abcellera.com.
AbCellera (NASDAQ: ABCL) will disclose its full year 2022 financial results on February 21, 2023, during a conference call at 2:00 p.m. PT (5:00 p.m. ET). A live audio webcast will be available on AbCellera's Investor Relations website, with a replay following the event. AbCellera is a biotechnology firm that focuses on identifying antibodies through the analysis of natural immune systems, aiding drug developers in creating treatments for various diseases. The company's partnerships span large pharmaceutical firms to small biotechs, enhancing efficiency in drug development.
The United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera (Nasdaq: ABCL), rejecting Berkeley Lights’ challenge to the validity of AbCellera’s U.S. Patent No. 10,087,408.
This patent pertains to microfluidic devices for cell culture and monitoring. Berkeley Lights previously filed multiple petitions with the PTAB, all of which have now been rejected. AbCellera expressed satisfaction with the decision and plans to proceed with its pending patent infringement lawsuit against Berkeley Lights. This outcome reinforces the strength of AbCellera's intellectual property portfolio.
AbCellera (Nasdaq: ABCL) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET). Executives from AbCellera will present, with a live audio webcast available on the company's Investor Relations website. A replay will be accessible after the presentation. AbCellera is a technology company focused on analyzing natural immune systems to discover antibodies for drug development, collaborating with pharmaceutical and biotechnology firms to expedite and enhance their drug development processes.
AbCellera (Nasdaq: ABCL) has initiated a strategic collaboration with AbbVie (NYSE: ABBV) targeting the development of therapeutic antibodies. This multi-year partnership aims to leverage AbCellera's innovative antibody discovery capabilities for up to five targets across various indications. AbCellera will receive research payments, clinical milestones, and royalties from product sales, indicating potential significant revenue streams. CEO Carl Hansen emphasized the collaboration's focus on solving complex antibody discovery challenges to address critical health issues.
Rallybio (Nasdaq: RLYB) and AbCellera (Nasdaq: ABCL) have formed a strategic alliance to develop antibody-based therapeutics for rare diseases. This collaboration combines AbCellera's antibody discovery capabilities with Rallybio's expertise in clinical development. The companies aim to co-develop up to five therapeutic targets, enhancing Rallybio's pipeline and addressing unmet needs in rare metabolic diseases. Both CEOs emphasized the potential for transformative medicines through this partnership.
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) have announced a strategic alliance aimed at developing novel antibody-based therapeutics for rare diseases. This multi-year collaboration combines AbCellera's advanced antibody discovery capabilities with Rallybio's expertise in rare disease clinical development. The partnership will focus on co-developing up to five therapeutic targets, starting with rare metabolic diseases, addressing significant unmet medical needs. Both companies aim to accelerate drug development and improve patient outcomes.
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 37th Annual Meeting, highlighting a diverse panel of CD3-binding antibodies for potential cancer treatments. The research includes proof-of-concept studies demonstrating T-cell engagers that effectively kill cancer cells while minimizing cytokine release. The company aims to enhance the development of bispecific antibodies, addressing the challenges of T-cell activation and specificity. AbCellera's advancements underscore its rapid antibody discovery capabilities and potential market impact.
AbCellera (Nasdaq: ABCL) reported impressive Q3 2022 financial results, with total revenue of $101.4 million, up from $5.5 million year-over-year. The company achieved net earnings of $26.6 million, or $0.09 per share, reversing a net loss of ($21.4 million) in Q3 2021. Program starts increased by 33% to a cumulative total of 92, and the number of molecules in clinical trials rose to 7. With a strong cash position of $868 million, AbCellera is well-positioned for future growth in antibody discovery.
AbCellera (Nasdaq: ABCL) announced participation in two major investor conferences. The company will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 3:50 p.m. PT, and at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:30 a.m. PT. Live webcasts will be available on AbCellera's Investor Relations website, with replays following the events. AbCellera is focused on leveraging natural immune systems to discover antibodies for drug development.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
